Pharmacology of thalidomide

Seminars in Hematology

Volumn 37, Issue 1 SUPPL. 3, 2000, Pages 5-14

  Stirling, David I ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APHTHOUS ULCER; ARTICLE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG INDUCED DISEASE; DRUG MECHANISM; ERYTHEMA NODOSUM LEPROSUM; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; WASTING SYNDROME;

EID: 0034063332     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(00)90077-5     Document Type: Article

References (97)

1. M Sherman S Strauss Thalidomide: A twenty-five year perspective Food Drug Cosmetic Law J 41 1986 458 466
2. GW Muller Thalidomide: From tragedy to new drug discovery Chemtech 1997 21 25
3. GW Mellin M Katzenstein The saga of thalidomide (concluded): Neuropathy to embryopathy, with case reports of congenital anomalies N Engl J Med 267 1962 1238 1244
4. J Sheskin Thalidomide in the treatment of lepra reactions Clin Pharmacol Ther 6 1965 303 306
5. RC Hastings JR Trautman CD Enna Thalidomide in the treatment of erythema nodosum leprosum: With a note on selected laboratory abnormalities in erythema nodosum leprosum Clin Pharmacol Ther 11 1970 481 487
6. CGS Iyer J Languillon K Ramanujam WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients Bull World Health Org 45 1971 719 732
7. J Sheskin J Convit Results of a double blind study of the influence of thalidomide on the lepra reaction Int J Lepr 37 1969 135 146
8. MFR Waters An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum Lepr Rev 42 1971 26 42
9. P Calderon M Anzilotti R Phelps Thalidomide in dermatology: New indications for an old drug Int J Dermatol 36 1997 881 887
10. D Stirling M Sherman S Strauss Thalidomide: A surprising recovery J Am Pharm Assoc 37 1997 306 313
11. DI Stirling Thalidomide anits impact in dermatology Semin Cutan Med Surg 17 1998 231 242
12. P Haslett VH Freedman G Kaplan The emerging role of thalidomide therapy in HIV-infected patients Infect Med 14 1997 393 398
13. P Haslett VH Freedman G Kaplan The emerging role of thalidomide therapy in HIV-infected patients Infect Med 14 1997 405 406
14. LN Alexander CM Wilcox A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers AIDS Res Hum Retroviruses 13 1997 301 304
15. JM Jacobson JS Greenspan J Spritzler Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection N Engl J Med 336 1997 1487 1493
16. EP Sampaio EN Sarno R Galilly Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes J Exp Med 173 1991 699 703
17. RJ D'Amato MS Loughnan E Flynn Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082 4085
18. BM Kenyon F Browne RJ D'Amato Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Eye Res 64 1997 971 978
19. J Folkman Tumor angiogenesis: Therapeutic implications N Engl J Med 285 1971 1182 1186
20. J Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
21. J Folkman Clinical applications of research on angiogenesis N Engl J Med 333 1995 1757 1763
22. VW Li RD Folkerth H Watanabe Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours Lancet 344 1994 82 86
23. N Munshi CS Wilson J Penn Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies Blood 92 suppl 1 1998 98a abstr
24. M Nguyen H Watanabe AE Budson Elevated levels of an angiogenic peptide, basic growth factor, in the urine of patients with a wide spectrum of cancers J Natl Cancer Inst 86 1994 356 361
25. AR Perez-Atayde SE Sallan U Tedrow Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 150 1997 815 821
26. SV Rajkumar R Fonseca TE Witzig Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma Leukemia 13 1997 469 472
27. D Ribatti A Vacca B Nico Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma Br J Cancer 79 1999 451 455
28. A Vacca M Di Loreto D Ribatti Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44 Am J Hematol 50 1995 9 14
29. A Vacca D Ribatti M Presta Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 1999 3064 3073
30. A Vacca D Ribatti L Roncali Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 1994 87 1994 503 508
31. T Eisen C Boshoff MM Vaughan Antiangiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: A phase II study Proc Am Soc Clin Oncol 17 1998 441a (abstr)
32. WD Figg R Bergen O Brawley Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC) Proc Am Soc Clin Oncol 16 1997 333a (abstr)
33. HA Fine JS Loeffler A Kyritsis A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas Proc Am Soc Clin Oncol 16 1997 385a (abstr)
34. T Kotoh D Kumar Dhar R Masunaga Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice Surgery 125 1999 536 544
35. G Long J Vredenburgh DA Rizzieri Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer Proc Am Soc Clin Oncol 17 1998 181a (abstr)
36. P Politi G Reboredo M Losso Phase I trial of thalidomed (T) in AIDS-related Kaposi sarcoma (KS) Proc Am Soc Clin Oncol 17 1998 41a (abstr)
37. GM Marx JA Levi DR Bell A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of advanced cancer Proc Am Soc Clin Oncol 18 1999 454a (abstr)
38. S Singhal J Mehta P Eddlemon Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM) Blood 92 Suppl 1 1998 318a abstr
39. ™ (thalidomide) prescribing information September 1998 Celgene Corporation Warren, NJ
40. S Tseng G Pak K Washenik Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses J Am Acad Dermatol 35 1996 969 979
41. M Reist P-A Carrupt E Francotte Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites Chem Res Toxicol 11 1998 1521 1528
42. T Eriksson S Björkman B Roth Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide Chirality 7 1995 44 52
43. T-L Chen GB Vogelsang BG Petty Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers Drug Metab Dispos 17 1989 402 405
44. WD Figg S Raje KS Bauer Pharmacokinetics of thalidomide in an elderly prostate cancer population J Pharm Sci 88 1999 121 125
45. SC Piscitelli WD Figg B Hahn Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients Antimicrob Agents Chemother 41 1997 2797 2799
46. MR Scheffler W Colburn KA Kook Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics Clin Pharmacol Ther 65 1999 483 490
47. GF Somers Pharmacological properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug Br J Pharmacol 15 1999 111 116
48. SK Teo WA Colburn SD Thomas Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers J Clin Pharmacol 39 1999 1162 1168
49. JW Faigle H Keberle W Riess The metabolic fate of thalidomide Experientia 18 1962 389 397
50. C Ludwak-Mann K Schmid H Keberle Thalidomide in rabbit semen Nature 214 1967 1019
51. KS Bauer SC Dixon WD Figg Inhibition oangiogenesis by thalidomide requires metabolic activation, which is species-dependent Biochem Pharmacol 55 1998 1827 1834
52. H Schumacher RL Smith RT Williams The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species Br J Pharmacol 25 1998 338 351
53. H Schumacher RL Smith RT Williams The metabolism of thalidomide: The spontaneous hydrolysis of thalidomide in solution Br J Pharmacol 25 1965 324 337
54. S Fabro H Schumacher RL Smith The metabolism of thalidomide: Some biological effects of thalidomide and its metabolites Br J Pharmacol 25 1965 352 362
55. D Tsambaos K Bolsen S Georgiou Effects of oral thalidomide on rat liver and skin microsomal P450 isoenzyme activities and on urinary porphyrin excretion: Interaction with oral hexachlorobenzene Arch Dermatol Res 286 1994 347 349
56. H Wiener P Krivanek E Tuisl Induction of drug metabolism in the rat by taglutimide, a sedative-hypnotic glutarimide derivative Eur J Drug Metab Pharmacokinet 5 1980 93 97
57. CB Trapnell SR Donahue JM Collins Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone Clin Pharmacol Ther 64 1998 597 602
58. J Schiller Early rrials of antiangiogenic agents Adv Oncol 15 1999 3 10
59. Barlogie B, Desikan R, Munshi N, et al. Single course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM). Blood 92:273b (suppl 1, abstr)
60. Y Kakeji BA Teicher Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents Invest New Drugs 15 1997 39 48
61. M Nguyen C Tran S Barsky Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies Int J Oncol 10 1997 965 969
62. BA Teicher SA Holden G Ara Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents Int J Cancer 57 1994 920 925
63. Z Cao WR Joseph WL Browne Thalidomide increases both intra-tumoural tumour necrosis factor-production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid Br J Cancer 80 1999 716 723
64. L-M Ching Z-F Xu BH Gummer Effect of thalidomide on tumor necrosis factor production and anti-tumor activity induced by 5,6-dimethylxanthenone-4-acetic acid Br J Cancer 72 1995 339 343
65. AL Moreira EP Sampaio A Zmuidzinas Thalidomide exerts its inhibitory action on tumor necrosis factor by enhancing mRNA degradation J Exp Med 177 1993 1675 1680
66. RB Oliveira MO Moraes EB Oliveira Neutrophils isolated from leprosy patients release TNF-α and exhibit accelerated apoptosis in vitro J Leukoc Biol 65 1999 364 371
67. JL Tavares A Wangoo P Dilworth Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages Respir Med 91 1997 31 39
68. JD Klausner VH Freedman G Kaplan Thalidomideas an anti-TNF-α inhibitor: Implications for clinicaluse Clin Immunol Immunopathol 81 1996 219 223
69. JD Klausner S Makonkawkeyoon P Akarasewi The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection J Acquit Immune Defic Syndr Hum Retrovirol 11 1996 247 257
70. S Makonkawkeyoon RNR Limson-Pobre AL Moreira Thalidomide inhibits the replication of human immunodeficiency virus type 1 Proc Natl Acad Sci USA 90 1993 5974 5978
71. S Dunzendorfer P Schratzberger N Reinisch Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine and endotoxin-activated endothelium Naunyn Schmiedebergs Arch Pharmacol 356 1997 529 535
72. TL Rowland SM McHugh J Deighton Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells Immunopharmacology 40 1998 11 20
73. BE Turk H Jiang JO Liu Binding of thalidomide to 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor production Proc Natl Acad Sci USA 93 1996 7552 7556
74. L-M Ching WL Browne R Tchernegovski Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factoralpha and enhancement of anti-tumour activity Br J Cancer 78 1998 336 343
75. M Carlesimo S Giustini A Rossi Treatment of cutaneous and pulmonary sarcoidosis with thalidomide J Am Acad Dermatol 32 1995 866 869
76. JL Jorizzo FC Schmalsteig AR Solomon Thalidomide effects in Behçet's syndrome and pustular vasculitis Arch Intern Med 146 1986 878 881
77. H Larsson Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217) J Int Med 228 1990 405 407
78. DM McCarthy EJ Kanfer AJ Barrett Thalidomide for the therapy of chronic graft-versus-host disease following allogeneic bone marrow transplantation Biomed Pharmacother 43 1989 693 697
79. PT Postema P den-Haan PM van-Hagen Treatment of colitis in Behcet's disease with thalidomide Eur J Gastroenterol Hepatol 8 1996 929 931
80. L Thomas B Ducros T Secchi Successful treatment of adult's Langerhans cell histiocytosis with thalidomide: Reports of two cases and literature review Arch Dermatol 129 1993 1261 1264
81. GB Vogelsang ER Farmer AD Hess Thalidomide for the treatment of chronic graft-versus-host disease N Engl J Med 326 1992 1055 1058
82. LP Fernandez PG Schlegel J Baker Does thalidomide affect IL-2 response and production? Exp Hematol 23 1995 978 985
83. RJ Keenan G Eiras GJ Burckart Immunosuppressive properties of thalidomide: Inhibition of in-vitro lymphocyte proliferation alone and in combination with cyclosporin or FK506 Transplantation 52 1991 908 910
84. B Moncada ML Baranda R González-Amaro Thalidomide effect on T cell subsets as a possible mechanism of action Int J Lepr 53 1985 201 205
85. P Haslett M Hempstead C Seidman The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus AIDS Res Hum Retroviruses 13 1997 1047 1054
86. + subset J Exp Med 187 1998 1885 1892
87. SM McHugh IR Rifkin J Deighton The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigenstimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol 99 1995 160 167
88. + cells in the peripheral blood Lepr Rev 63 1992 5 11
89. H Geitz S Handt K Zwingenberger Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Immunopharmacology 31 1996 213 221
90. AC Nogueira R Neubert H Helge Thalidomide and the immune system: Simultaneous up- and down-regulation of different integrin receptors on human white blood cells Life Sci 55 1994 77 92
91. DR Moller M Wysocka BM Greenlee Inhibition of IL-2 production by thalidomide J Immunol 159 1997 5157 5161
92. EJ Shannon F Sandoval Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative Immunopharmacology 31 1995 109 116
93. V Gunzler Thalidomide in human immunodeficiency virus (HIV) patients: A review of safety considerations Drug Safety 7 1992 116 134
94. ™: A comprehensive program for controlling and monitoring access to thalidomide Clin Ther 21 1992 319 330
95. IK Aronson R Yu DP West Thalidomideinduced peripheral neuropathy Arch Dermatol 120 1984 1466 1470
96. OJ Clemmensen P Zander Olsen KE Anderson Thalidomide neurotoxicity Arch Dermatol 120 1984 338 341
97. PM Fullerton DJ O'Sullivan Thalidomide neuropathy: A clinical, electrophysiological, and histological follow-up study J Neurol Neurosurg Psychiatr 31 1968 543 551